Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Operating Expenses (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Operating Expenses for 11 consecutive years, with $57.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses fell 6.66% year-over-year to $57.2 million, compared with a TTM value of $209.6 million through Dec 2025, changed 0.48%, and an annual FY2025 reading of $209.6 million, changed 0.48% over the prior year.
  • Operating Expenses was $57.2 million for Q4 2025 at Spyre Therapeutics, roughly flat from $56.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $159.9 million in Q2 2023 and bottomed at $18.2 million in Q1 2021.
  • Average Operating Expenses over 5 years is $41.6 million, with a median of $33.9 million recorded in 2022.
  • The sharpest move saw Operating Expenses surged 593.92% in 2023, then plummeted 72.4% in 2024.
  • Year by year, Operating Expenses stood at $24.1 million in 2021, then dropped by 19.75% to $19.3 million in 2022, then skyrocketed by 137.53% to $45.9 million in 2023, then surged by 33.41% to $61.3 million in 2024, then fell by 6.66% to $57.2 million in 2025.
  • Business Quant data shows Operating Expenses for SYRE at $57.2 million in Q4 2025, $56.9 million in Q3 2025, and $41.9 million in Q2 2025.